Pharmaceutical Evaluation Contract Services
The accuracy of blood cells produces the accuracy of evaluation.
Our company has realized a highly accurate "contract service for drug evaluation" through the mass production of human leukocytes using iPS technology, enabling rapid and reliable drug development. In the fields of infectious diseases and immunology/oncology research and evaluation, obtaining stable quantities of quality blood cells has been a significant bottleneck. However, we have successfully addressed this issue by using iPS technology (regenerative medicine technology) to mass-produce "stimulus-naive myeloid cells (dendritic cells)" with identical genetic information. This has dramatically improved the accuracy and speed of drug evaluation. We can also produce blood cells from individual blood samples, allowing for the simultaneous realization of a simple evaluation system and a wide range of evaluation designs. 【Our Strengths】 - Ability to procure myeloid cells, which are typically scarce, in large and stable quantities - Use of "stimulus-naive dendritic cells," ideal for research and evaluation - Capability to produce blood cells from provided blood samples - Possibility to construct evaluation systems using mature dendritic cells as antigen-presenting cells *For more details, please download the PDF or feel free to contact us.
- 企業：マイキャン・テクノロジーズ
- 価格：Other
